Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Date:8/8/2013

th ABRAXANE® (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) and gemcitabine in approximately 130 patients with previously untreated metastatic pancreatic cancer. Plans for Rainier were announced in May 2013 and patient enrollment is expected to begin in mid-2013.
  • The Pacific™ Trial is an investigator-sponsored, randomized, open-label Phase 2 trial evaluating apatorsen in approximately 80 men with metastatic CRPC who are experiencing rising prostate-specific antigen (PSA) while receiving Zytiga® (abiraterone acetate). The trial was initiated in December 2012 and is currently enrolling at sites in the United States and Canada.
  • Second Quarter 2013 Financial Update and Results

  • Revenue for the three and six months ended June 30, 2013 increased to $6.3 million and $11.4 million, respectively. This compares to $2.4 million and $3.7 million, respectively, in the same periods in 2012. The increases in 2013 compared to 2012 were due to an increase in revenue earned through the Company's strategic collaboration with Teva, as a result of the clinical development activities associated with the AFFINITY trial that was initiated in August 2012.
  • Total operating expenses for the three and six months ended June 30, 2013 increased to $15.7 million and $29.1 million, respectively, compared to $8.4 million and $15.2 million, respectively, in the same periods in 2012. The increases in 2013 compared to 2012 were due primarily to increased clinical trial expenses associated with patient enrollment in the AFFINITY and Borealis-1 trials, higher costs directly associated with efforts to increase patient enrollment, increased employee expenses due to an increase in the number of employees to support our clinical development activities and increased toxicology and preclinical expenses related to apatorsen. These increases were partially off
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
    2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
    3. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
    4. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
    5. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
    6. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    7. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference
    8. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
    9. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
    10. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
    11. Auxilium Pharmaceuticals, Inc, Announces Second Quarter 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- Full Service CRO ... the new Vice President of Business Development. Peter has ... in a number of different business development positions with ... positions were primarily related to business development/sales management and ... 30 years makes him a key and strategic asset ...
    (Date:7/25/2014)... MARLTON, N.J. , July 25, 2014 /PRNewswire/ ... visibility, brand protection and serialization solutions, has recently ... Business" that addresses current and future needs ... solutions for the old supply chain model no ... advances in technology, including the growth of mobile ...
    (Date:7/25/2014)... 25, 2014  IDEXX Laboratories, Inc. (NASDAQ: ... quarter of 2014 increased 11% versus the prior year ... for the second quarter of 2014 versus the prior ... in distributor inventory 2 . Earnings per diluted share ... 11% from the prior year period to $1.10."In the ...
    Breaking Medicine Technology:Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2Acsis Addresses Questions on the Modern Supply Chain 2IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23IDEXX Laboratories Announces Second Quarter Results 24IDEXX Laboratories Announces Second Quarter Results 25IDEXX Laboratories Announces Second Quarter Results 26IDEXX Laboratories Announces Second Quarter Results 27IDEXX Laboratories Announces Second Quarter Results 28IDEXX Laboratories Announces Second Quarter Results 29IDEXX Laboratories Announces Second Quarter Results 30IDEXX Laboratories Announces Second Quarter Results 31IDEXX Laboratories Announces Second Quarter Results 32IDEXX Laboratories Announces Second Quarter Results 33IDEXX Laboratories Announces Second Quarter Results 34
    ... 2010 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: ... fast-growing, profitable developer, manufacturer and seller of medicine and ... today that the Company will effect a two-for-one reverse ... minimum share price requirements in connection with its application ...
    ... 31, 2010 CVS Caremark (NYSE: CVS ... to acquire the Medicare Part D business of Universal ... billion.  Universal American is a leading Medicare Prescription Drug Plan ... acquisition will more than double the size of CVS ...
    Cached Medicine Technology:Lotus Pharmaceuticals Announces Approval of Reverse Stock Split 2CVS CAREMARK to Purchase Universal American's Medicare Part D Business 2CVS CAREMARK to Purchase Universal American's Medicare Part D Business 3CVS CAREMARK to Purchase Universal American's Medicare Part D Business 4
    (Date:7/26/2014)... As reported by Lauren Hunter of ... 3 factors: smaller spaces, multi-generational access, and water consumption. ... 2014 lists, including this article on Freshome , ... a leading manufacturer of steam bath generators, has noticed ... smaller spaces and an effort to reduce water consumption. ...
    (Date:7/26/2014)... 26, 2014 As reported in ... 23rd, new research by Palo Alto Networks shows that ... playbook, now focusing more on businesses and their digital ... become increasingly wise to their tactics over the years. ... Joe Caruso, talks about the evolution of 419 scams ...
    (Date:7/26/2014)... “Healthy teeth are important, and having your teeth cleaned regularly ... Health Center of Snohomish County (CHC) in their article, “ ... integration of medical and dental care is the best way ... encourage regular cleanings and checkups not only with a family ... adults will find knowledgeable and friendly staff that ...
    (Date:7/26/2014)... July 26, 2014 Multiple sclerosis ... disseminata, is an inflammatory disease in which the ... and spinal cord are damaged. This damage disrupts ... to communicate, resulting in a wide range of ... psychiatric problems. Multiple sclerosis takes several forms, with ...
    (Date:7/26/2014)... (PRWEB) July 26, 2014 The U.S. Food ... list that includes a new medication guide for AndroGel to ... serious side-effect of taking the topical low testosterone medication, notes ... AbbVie Inc., the makers of the low testosterone theapy drug, ... of pain, swelling or redness as signs of a blood ...
    Breaking Medicine News(10 mins):Health News:Amerec Finds Bathroom Design Trends Change Based on Water Consumption and Other Factors 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 3Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 4Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 5Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 6Health News:Common Dental Care Questions Answered by Community Health Center of Snohomish County in Recent Article 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 3Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5
    ... A residential summer weight-loss camp markedly improved obese ... Pediatrics reports. A Saint Louis University ... index (BMI), physical fitness and blood pressure. "Weight ... the social environment to be successful," said Nadim Kanafani, ...
    ... diabetes may be related to trend toward less sleep, ... Adding to the many reasons why people should get adequate ... cause insulin resistance, a component of type 2 diabetes. , ... measured after a night of normal sleep (about eight hours) ...
    ... levels increased more than 50% after timing change, researchers say ... make better use of a vitamin D supplement if you ... Researchers at the Cleveland Clinic examined 17 patients with vitamin ... period of two to three months, the patients were told ...
    ... May 2010 -- An international team of researchers has ... with HER2 over-expressing breast cancer do not respond to ... research, presented at the IMPAKT Breast Cancer Conference in ... clinical trial design and treatment strategies in HER2 over-expressing ...
    ... to 10 million women take hormone therapies, which are ... hormones lost from inactive ovaries. Progestin is a hormone ... of estrogen therapy on the uterus. In studies sponsored ... found that estrogen and progestin in hormone therapies increase ...
    ... ... held liable of confirmation fraud if an employee responds falsely to a confirmation request. ... requests, new guidance from the standards-setting boards supporting the use of secure electronic confirmations now ... ...
    Cached Medicine News:Health News:The biggest winners: Summer campers 2Health News:One Sleepless Night Ups Insulin Resistance 2Health News:Estrogen receptor status of HER2+ breast cancer correlates with response to anti-HER therapies 2Health News:Breast cancer metastasis increases after estrogen and progestin hormone therapies, MU study finds 2Health News:Brian Fox to Speak on Audit Confirmation Fraud at the 2010 IAPP Annual Forum and Expo 2
    ... Mono-M Test is a qualitative enzyme ... to Paul-Bunnell heterophil, Epstein-Barr virus capsid ... used in conjunction with Mono-G Test, ... serodiagnosis of infectious (EBV) mononucleosis and ...
    ... The ImmunoWELL VCA IgM Test is an ELISA ... to Epstein-Barr Virus viral capsid antigen (VCA) in ... used in conjunction with other testing such as ... EBV early antigen tests and/or heterophile tests, the ...
    The ImmunoWELL Borrelia (Lyme) Test is an enzyme immunoassay (EIA) for the qualitative and/or semiquantitative detection of Borrelia burgdorferi total antibodies (IgG, IgM, and IgA) in serum and is u...
    ... ImmunoDOT is dot-blot assay system combining ... microwell, a purified antigen set at a ... membrane. Reactivity is detected using the same ... assays., ,ENA/DNA combines antigens detected in Auto ...
    Medicine Products: